After Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VCMichael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive Share XAfter Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VChttps://pharmaphorum.com/news/after-alzheimers-trial-woes-biogens-rd-chief-quits-to-head-up-biotech-vc/
Combating chronic diseases through technology and collaborationBy 2050, 2.1bn people globally will be aged 60 or over. That’s more than double the 962m recorded in 2017. This lengthening of life is closely Share XCombating chronic diseases through technology and collaborationhttps://pharmaphorum.com/digital/combating-chronic-diseases-through-technology-and-collaboration/
BioXcel to trial Apple Watch-drug combination to prevent Alzheimer’s agitation episodesUS biotech BioXcel Therapeutics hopes to use wearable digital devices such as the Apple Watch to predict whether Share XBioXcel to trial Apple Watch-drug combination to prevent Alzheimer’s agitation episodeshttps://pharmaphorum.com/news/bioxcel-to-trial-apple-watch-drug-combination-to-prevent-alzheimers-agitation-episodes/
Citing phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccineAfter trial failure upon trial failure in Alzheimer’s disease will big pharma be prepared to fund a trial Share XCiting phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccinehttps://pharmaphorum.com/r-d/uk-biotech-axon-looks-for-big-pharma-investment-for-alzheimers-vaccine/
The challenges of measuring dementiaOxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, Share XThe challenges of measuring dementiahttps://pharmaphorum.com/views-and-analysis/the-challenges-of-measuring-dementia/
Finding the big picture for Alzheimer’sThe $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’ Share XFinding the big picture for Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/
Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
Neurametrix aims to expand Alzheimer’s typing test in Pacific regionUS medical device firm Neurametrix has struck an agreement with N-Strategy Consulting Services (NSCS) to invest in a Share XNeurametrix aims to expand Alzheimer’s typing test in Pacific regionhttps://pharmaphorum.com/news/neurametrix-aims-to-expand-alzheimers-typing-test-in-pacific-region/
Novartis and Amgen axe BACE drug for Alzheimer’sAnother Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end Share XNovartis and Amgen axe BACE drug for Alzheimer’shttps://pharmaphorum.com/news/novartis-and-amgen-axe-bace-drug-for-alzheimers/
